Biological Technologies Office (DARPA)

SentinelOne® Achieves 100% Prevention and Detection in MITRE Engenuity ATT&CK Evaluation

Retrieved on: 
Wednesday, September 20, 2023
Data Management, Security, Apps, Applications, Technology, Software, Internet, Biological Technologies Office (DARPA), Organization, Singularity, MITRE, NYSE, Arms industry, Risk management, SentinelOne

For the fourth consecutive year, SentinelOne Singularity XDR achieved 100% prevention, 100% detection and zero detection delays with no configuration changes.

Key Points: 
  • For the fourth consecutive year, SentinelOne Singularity XDR achieved 100% prevention, 100% detection and zero detection delays with no configuration changes.
  • These results demonstrate the Singularity Platform’s unique ability to autonomously defend against even the most complex threats, right out-of-the-box.
  • Key results achieved by SentinelOne Singularity include:
    100% Protection Across Operating Systems (13 of 13 MITRE ATT&CK tests): Attacks happen fast.
  • 100% Detection (18 of 18 attack steps): In today’s dynamic threat landscape, solving problems after they occur won’t cut it.

SentinelOne® and Mandiant Bolster Strategic Partnership, Empowering Organizations to Harden Defenses and Proactively Protect Against the Latest Threats

Retrieved on: 
Monday, September 18, 2023
Data Management, Security, Technology, Mobile, Wireless, Software, Networks, Internet, Cloud, Biological Technologies Office (DARPA), Organization, Partnership, Intelligence, Environment, NYSE, Risk, Google Cloud, Risk management, Mandiant, SentinelOne

“The cybersecurity threat landscape is rapidly evolving, with attacks becoming more numerous and sophisticated by the minute,” said Ric Smith, Chief Product and Technology Officer, SentinelOne.

Key Points: 
  • “The cybersecurity threat landscape is rapidly evolving, with attacks becoming more numerous and sophisticated by the minute,” said Ric Smith, Chief Product and Technology Officer, SentinelOne.
  • “Over the last 18 months, Mandiant and SentinelOne have partnered to deliver highly adaptable and intelligence-led security solutions to customers,” said Marshall Heilman, Mandiant CTO, Google Cloud.
  • “The expanded strategic partnership marks a major milestone in our journey to democratize our threat intelligence and make it actionable for everyone.
  • A pioneer and leader in autonomous cybersecurity, SentinelOne provides a market-leading AI-powered platform to protect the entire enterprise.

Aquyre Biosciences wins top award from French American Chamber of Commerce, New England

Retrieved on: 
Friday, May 19, 2023
Biotechnology, General Health, Health, Oncology, Biological Technologies Office (DARPA), Biopsy, Diagnosis, Commerce, Nursing, Medical imaging

Aquyre Biosciences, Inc. the creator of CelTivity, the industry leader in two-minute lung biopsy adequacy assessment, today announced that Aquyre Biosciences and its founder Bertrand De Poly have been recognized with the 2023 FAB Life Sciences Award, from the French American Chamber of Commerce, New England.

Key Points: 
  • Aquyre Biosciences, Inc. the creator of CelTivity, the industry leader in two-minute lung biopsy adequacy assessment, today announced that Aquyre Biosciences and its founder Bertrand De Poly have been recognized with the 2023 FAB Life Sciences Award, from the French American Chamber of Commerce, New England.
  • The FAB Life Sciences Award celebrates French and American companies and entrepreneurs throughout New England that make significant and positive contributions and achievements in the field of life sciences.
  • “I am honored to have been nominated for this prestigious award,” said Bertrand De Poly, Founder and Chief Strategy and Technology Officer.
  • This past year Aquyre celebrated a major procedural milestone of over 500 biopsy analysis performed using their CelTivity system.

Genprex to Present at Bioprocessing Summit Conference

Retrieved on: 
Monday, March 13, 2023
Diabetes, Date, Central European, Conference, Patient, Biological Technologies Office (DARPA), CDMO, Drug development, Cancer, Partnership, Pharmaceutical industry

AUSTIN, Texas, March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona, Spain.

Key Points: 
  • AUSTIN, Texas, March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona, Spain.
  • Dr. Kumar will deliver the following presentation:
    Speaking Date and Time: Wednesday, March 15 at 8:30 a.m. Central European Time
    "Dramatic increase in mergers and acquisitions within the global CDMO market has changed the landscape for advancing the development of disruptive innovative gene therapies.
  • This has encouraged CDMOs to provide integrated services to advance drug development but can be a financial burden on clinical stage companies due to potentially higher costs for services and licensing fees, and can add delays in timelines for regulatory submissions," noted Dr. Kumar.
  • "Managing these headwinds through better partnership with CDMOs is key to overcoming these challenges as together we work to bring life-altering new gene therapy treatments to patients battling diseases of unmet medical need."

Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders

Retrieved on: 
Friday, January 27, 2023
CNS, AAV, Traffic barrier, Central nervous system disease, Spark Therapeutics, ROG, Central nervous system, Patient, RO, CED, Biological Technologies Office (DARPA), Huntington's disease, Hoffmann-La Roche, Degenerative disease, Brain, Research, Therapy, Pharmaceutical industry, Medical device, Spark

Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark’s leading AAV platform.

Key Points: 
  • Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark’s leading AAV platform.
  • "There continues to be high unmet medical need in treating CNS disorders, and at Spark we see the significant potential of gene therapy to provide new treatment options for patients," said Federico Mingozzi, Chief Science & Technology Officer, Spark Therapeutics.
  • Neurochase is developing a proprietary drug delivery system and this collaboration enables Spark to develop selected gene therapies for CNS disorders using the Neurochase technology, which aims to improve targeted delivery of AAV gene therapy to neural structures using the method of Convection Enhanced Delivery (CED).
  • "Applying CED-based delivery systems for AAV gene therapies is an emerging strategy for the treatment of neurological disorders," said Sharon Kane, CEO, Neurochase.

Renee Wegrzyn Slated to Lead New Advanced Research Projects Agency for Health

Retrieved on: 
Monday, September 12, 2022
Risk, Health, Therapy, Agriculture, Alexander von Humboldt Foundation, Biological Technologies Office (DARPA), COVID-19, Gene editing, NYSE, Infection, Center, U.S. Securities and Exchange Commission, BTO, Alexander von Humboldt, ARPA, Computer, DARPA, Face, Acquisition, K-12, Soarin' Eagle, Synthetic biology, Program, Business, Forward-looking statement, Georgia Institute of Technology College of Computing, Cancer, Technology, BS, General manager, Doctor of Philosophy, Food, Ginkgo Bioworks, White House, Research, DNA, Biotechnology, COVID-19 testing, SEC, Business development, Disease, Biology, Management, Pharmaceutical industry, Biosecurity, Ginkgo

BOSTON, Sept. 12, 2022 /PRNewswire/ -- The White House today announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health ( ARPA-H ).

Key Points: 
  • BOSTON, Sept. 12, 2022 /PRNewswire/ -- The White House today announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health ( ARPA-H ).
  • Dr. Wegrzyn is currently the Vice President for Business Development at Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming.
  • ARPA-H was established in March 2022 to drive transformative health breakthroughs that cannot readily be accomplished through traditional research or commercial activity.
  • "Some of the problems we face every day - especially in health and disease - are so large they can seem insurmountable.

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

Retrieved on: 
Tuesday, September 6, 2022
DPP, COVID-19, Technology, Research, Syphilis, U.S. Securities and Exchange Commission, CLIA, Antibody, GLOBE, Â, POC, CDC, Patient, EUA, CE marking, Vertically transmitted infection, World, Serum, ANVISA, FDA, Confirmation, Disease, Biological Technologies Office (DARPA), Treponema pallidum, Immunoglobulin M, Blood, Infant, Hospital, Pregnancy Outcome Prediction (POP) study, HIV, Science and technology, PMA, Korea Disease Control and Prevention Agency, Serology, Immunoglobulin G, Private Securities Litigation Reform Act, Transport, Government, Infection, Policy, Congenital syphilis, Physician, Diagnosis, Center, Plasma, Annual report, Forward-looking statement, World Health Organization, Medical device, Vaccine, Pharmaceutical industry

Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II.

Key Points: 
  • Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II.
  • Chembio has previous experience in the field of rapid syphilis diagnostics through its successful development, validation, and commercialization of DPP HIV-Syphilis.
  • The Chembio DPP HIV-Syphilis Assay is a rapid serologic test for the detection of antibodies to HIV and/or the causative agent of syphilis, Treponema pallidum.
  • Additionally, Chembio has worked to develop a DPP Syphilis Screen and Confirm test, using a CDC licensed reagent with improved liposomal preparation on the nontreponemal test line.

Restore Hyper Wellness Adds to Its Leadership Team as It Continues Its Exponential Growth

Retrieved on: 
Wednesday, July 13, 2022
Women, Fitness & Nutrition, Men, Specialty, Alternative Medicine, Health, Consumer, General Health, Retail, Technology, Nursing, IV, SoulCycle, Multimedia, Johnson & Johnson, Solution, Diabetes, Risk management, Travel, CTO, Donnelly (surname), Travelocity, The Co Founder, Patient, Name, CrossFit, CEO, Love, Biological Technologies Office (DARPA), Music, Entrepreneurship, Founder, Investment, IM, Information officer, Hospital, General Atlantic, Cryotherapy, Software, Pharmaceutical industry, Restore, New Circadia, Medicare

We are excited to have Jeremy and Tony joining our leadership team and mission.

Key Points: 
  • We are excited to have Jeremy and Tony joining our leadership team and mission.
  • With Restore, Cheng and Donnelly are now reuniting to deliver on Restores mission of making Hyper Wellness accessible and affordable.
  • Launched in Austin, Texas in 2015, Restore Hyper Wellness (Restore) is the award-winning creator of an innovative new category of careHyper Wellness.
  • Restores mission is to make Hyper Wellness accessible and affordable so people can feel their best and do more of what they love.

Neurology and Human-Machine Interface Veteran Dr. Geoffrey Ling Joins Board of Trailblazing Neurotech Startup Phantom Neuro

Retrieved on: 
Tuesday, June 28, 2022
Science, Patient, CEO, Research, Engineering, Johns Hopkins School of Medicine, Connor, Phantom, Robotics, DARPA, Biomedical engineering, Nerve, Neurology, Biological Technologies Office (DARPA), Partnership, Quality of life, Johns Hopkins, JD, Medicine, AI, Safety, Phantom-x, MD, Medical device

AUSTIN, Texas and BALTIMORE, June 28, 2022 /PRNewswire/ -- Phantom Neuro, the first-of-its-kind neurotech startup that delivers a low power, high accuracy system for lifelike control of robotic orthopedic technologies, today announced the appointment of Dr. Geoffrey Ling to the technical advisory board. Dr. Ling is the current CEO of On Demand Pharmaceuticals and was previously the Founding Director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office, where he led DARPA's funding towards human-machine interactions. He joins renowned medical professors, seasoned executives and investors on the board.

Key Points: 
  • AUSTIN, Texas and BALTIMORE, June 28, 2022 /PRNewswire/ -- Phantom Neuro , the first-of-its-kind neurotech startup that delivers a low power, high accuracy system for lifelike control of robotic orthopedic technologies, today announced the appointment of Dr. Geoffrey Ling to the technical advisory board.
  • He joins renowned medical professors, seasoned executives and investors on the board.
  • I've had a front row seat to technological developments in medicine for the past 30+ years and oversaw many academic advancements that make Phantom Neuro possible today.
  • Phantom Neuro was born out of the suboptimal patient outcomes observed through real world clinical and engineering experience.

Scientific advances from Athenium Analytics enable climate intelligence to assess risks of severe weather and structural damageability

Retrieved on: 
Tuesday, February 15, 2022
API, Statistics, Wind, Risk, Grey, Weather, Solution, Biological Technologies Office (DARPA), United, Gauge, Insurance, Lists of disasters, Senior, Machine learning, Multimedia, Mississippi River, New product development, Software as a service, B cell, Risk management, Einsteinium

DOVER, N.H., Feb. 15, 2022 /PRNewswire/ -- Athenium Analytics , a leading provider of natural hazard and structural risk analytics, announced today the upcoming release of new capabilities essential to building climate intelligence.

Key Points: 
  • DOVER, N.H., Feb. 15, 2022 /PRNewswire/ -- Athenium Analytics , a leading provider of natural hazard and structural risk analytics, announced today the upcoming release of new capabilities essential to building climate intelligence.
  • "Scientific advancements and availability of new data are the driving factors behind the updates to our Gauge risk scores."
  • "Athenium welcomes this higher level of accountability and the value it creates for all stakeholders in advancing climate intelligence."
  • Athenium Analytics delivers powerful risk intelligence and SaaS solutions that allow enterprises to identify, measure and mitigate risk.